Maravai LifeSciences Holdings, Inc. (MRVI) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 14, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q2 FY2026, filed Aug 7, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the MRVI SEC filings page.
Maravai LifeSciences Holdings, Inc. (MRVI) reported $208.8M in revenue over the twelve months to Jun 30, 2026, down 5.0% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 7 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Maravai has shifted from a high-margin cash generator to a shrinking business where fixed costs overwhelm a much smaller revenue base.
Cash conversion deteriorated alongside profitability: operating cash flow moved from$536M in FY2022 to-$58M in FY2025. Free cash flow followed the same path, moving from$519M to-$71M , showing that earlier cash generation did not persist as the business contracted.
Revenue fell to
Short-term liquidity is not the immediate constraint: the current ratio was 6.6x and the reported liquidity comparison was 45.2 months of annual operating outflow. However, debt-to-equity reached 1.3x as equity declined to
Financial Health Signals
Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Maravai LifeSciences Holdings, Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Maravai LifeSciences Holdings, Inc. held $216.9M in cash, cash equivalents and investments at the end of fiscal year 2025, and its operations used $57.6M of cash that year. Cash Runway ranks emerging companies on the size of that balance against the outflow behind it, and Maravai LifeSciences Holdings, Inc. scores 66/100 among other emerging companies.
Not available for Maravai LifeSciences Holdings, Inc., and counted as zero in the overall score.
Maravai LifeSciences Holdings, Inc. spent $17.4M on research and development in fiscal year 2025, which was 4.3% of its operating costs that year. R&D Intensity ranks emerging companies on the share of operating costs that goes into research, and Maravai LifeSciences Holdings, Inc. scores 22/100 among other emerging companies.
Maravai LifeSciences Holdings, Inc. reported revenue of $185.7M in fiscal year 2025, against $259.2M in fiscal year 2024. Revenue Progress ranks emerging companies on the three-year path of that line, and Maravai LifeSciences Holdings, Inc. scores 19/100 among other emerging companies.
Not available for Maravai LifeSciences Holdings, Inc., and counted as zero in the overall score.
Maravai LifeSciences Holdings, Inc.'s cash, cash equivalents and investments came to $216.9M at the end of fiscal year 2025, against $558.2M of total liabilities. Balance Sheet ranks emerging companies on that comparison, and Maravai LifeSciences Holdings, Inc. scores 38/100 among other emerging companies.
Maravai LifeSciences Holdings, Inc. scores 2.34, placing it in the grey zone between 1.81 and 2.99. The score is driven primarily by a large market capitalization ($2.4B) relative to total liabilities ($558.2M). This signals moderate financial risk that warrants monitoring.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Maravai LifeSciences Holdings, Inc. passes 1 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), neither operating efficiency signal passes.
Maravai LifeSciences Holdings, Inc. reported a net loss of $130.8M while operations used $57.6M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Maravai LifeSciences Holdings, Inc. reported an operating loss of $215.3M against $27.0M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
Maravai LifeSciences Holdings, Inc. generated $51.4M in revenue in Q2 2026. This represents an increase of 8.5% from the same quarter a year earlier. Against the prior quarter it is down 21.9%.
Maravai LifeSciences Holdings, Inc.'s EBITDA was -$3.3M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 93.8% from the same quarter a year earlier. Against the prior quarter it is down 135.9%.
Maravai LifeSciences Holdings, Inc. reported -$12.4M in net income in Q2 2026. This represents an increase of 68.6% from the same quarter a year earlier. Against the prior quarter it is down 232.6%.
Maravai LifeSciences Holdings, Inc. earned -$0.08 per diluted share (EPS) in Q2 2026. This represents an increase of 70.4% from the same quarter a year earlier. Against the prior quarter it is down 300.0%.
Cash & Balance Sheet
Maravai LifeSciences Holdings, Inc. generated $3.6M in free cash flow in Q2 2026, representing cash available after capex. This represents an increase of 127.6% from the same quarter a year earlier. Against the prior quarter it is down 14.3%.
Maravai LifeSciences Holdings, Inc. held $70.1M in cash against $146.0M in long-term debt as of Q2 2026.
Not reported for Q2 2026.
Margins & Returns
Maravai LifeSciences Holdings, Inc.'s gross margin was 40.1% in Q2 2026, indicating the percentage of revenue retained after direct costs. This is up 23.8 percentage points from the same quarter a year earlier. Against the prior quarter it is down 11.1 percentage points.
Maravai LifeSciences Holdings, Inc.'s operating margin was -29.3% in Q2 2026, reflecting core business profitability. Against the prior quarter it is down 26.1 percentage points. No change is given against Q2 2025: its reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Maravai LifeSciences Holdings, Inc.'s net profit margin was -24.1% in Q2 2026, showing the share of revenue converted to profit. This is up 59.4 percentage points from the same quarter a year earlier. Against the prior quarter it is down 18.5 percentage points.
Maravai LifeSciences Holdings, Inc.'s ROE was -6.1% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is up 8.8 percentage points from the same quarter a year earlier. Against the prior quarter it is down 4.3 percentage points.
Capital Allocation
Maravai LifeSciences Holdings, Inc. invested $3.7M in research and development in Q2 2026. This represents a decrease of 24.2% from the same quarter a year earlier. Against the prior quarter it is down 4.8%.
Maravai LifeSciences Holdings, Inc. invested $370K in capex in Q2 2026, funding long-term assets and infrastructure. This represents a decrease of 87.1% from the same quarter a year earlier. Against the prior quarter it is down 91.7%.
Not reported for Q2 2026.
MRVI Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Revenue | $51.4M+8.5% | $65.8M+40.5% | $49.9M-11.8% | $41.6M-39.7% | $47.4M-31.7% | $46.9M-27.0% | $56.6M-23.7% | $69.0M+3.2% |
| Cost of Revenue | $30.8M-22.3% | $32.1M-17.9% | $37.0M-0.4% | $36.0M-2.2% | $39.6M+2.7% | $39.1M+2.1% | $37.2M+5.9% | $36.8M+0.3% |
| Gross Profit | $20.6M+165.8% | $33.7M+336.3% | $12.8M-33.8% | $5.7M-82.5% | $7.8M-74.8% | $7.7M-70.1% | $19.4M-50.3% | $32.2M+6.8% |
| R&D Expenses | $3.7M-24.2% | $3.9M-20.4% | $3.8M-16.9% | $3.8M-18.3% | $4.9M-0.9% | $4.9M-2.9% | $4.6M-0.7% | $4.7M+8.2% |
| SG&A Expenses | $32.1M-17.2% | $29.1M-26.5% | $31.4M-23.8% | $35.4M-9.4% | $38.7M-4.5% | $39.6M-3.2% | $41.2M+7.2% | $39.1M+0.6% |
| Operating Income | -$15.1M+77.2% | -$2.2M+95.6% | -$58.8M-55.9% | -$41.0M+75.2% | -$66.3M-393.1% | -$49.2M-160.7% | -$37.7M-427.3% | -$165.6M-974.2% |
| EBITDA | -$3.3M+93.8% | $9.2M+125.3% | -$46.4M-83.0% | -$27.8M+81.9% | -$53.1M-5133.6% | -$36.4M-405.7% | -$25.3M-793.9% | -$153.7M-3333.4% |
| Interest Expense | $4.8M-29.4% | $5.7M-15.2% | $6.6M-41.8% | $6.8M-49.8% | $6.8M-42.9% | $6.8M-37.6% | $11.3M-26.9% | $13.6M+17.2% |
| Income Tax | -$171K+96.0% | -$151K-193.2% | $6K+185.7% | -$92K-129.6% | -$4.3M-76.1% | $162K-40.2% | -$7K-100.0% | $311K+105.7% |
| Net Income | -$12.4M+68.6% | -$3.7M+87.5% | -$35.7M-38.1% | -$25.6M+73.7% | -$39.6M-304.4% | -$29.9M-147.9% | -$25.9M+79.4% | -$97.1M-1402.2% |
| EPS (Basic) | -$0.08+70.4% | -$0.02+90.5% | -$0.24-33.3% | -$0.18+73.5% | -$0.27-285.7% | -$0.21-133.3% | -$0.18+77.5% | -$0.68-1260.0% |
| EPS (Diluted) | -$0.08+70.4% | -$0.02+90.5% | -$0.24-33.3% | -$0.18+73.5% | -$0.27-285.7% | -$0.21-133.3% | -$0.18+77.5% | -$0.68-1260.0% |
| Diluted Shares (Avg) | 148M+2.6% | 146M+2.1% | N/A | 145M+2.2% | 144M+6.2% | 143M+8.4% | N/A | 142M+7.3% |
MRVI Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $603.7M-32.7% | $713.2M-25.7% | $770.6M-23.6% | $849.2M-33.6% | $897.0M-37.9% | $959.8M-33.6% | $1.0B-32.2% | $1.3B-43.6% |
| Current Assets | $155.7M-56.7% | $251.7M-33.1% | $296.3M-31.0% | $325.9M-52.0% | $359.8M-47.2% | $376.3M-43.7% | $429.1M-38.7% | $679.1M-3.1% |
| Cash & Equivalents | $70.1M-74.0% | $165.9M-41.8% | $216.9M-32.7% | $243.6M-57.9% | $269.9M-52.9% | $285.1M-49.3% | $322.4M-43.9% | $578.2M-0.2% |
| Short-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Inventory | $41.2M-11.7% | $40.5M-18.7% | $40.5M-19.1% | $45.3M-10.3% | $46.7M-5.4% | $49.8M-0.1% | $50.1M-2.6% | $50.5M+2.8% |
| Accounts Receivable | $31.1M+11.7% | $33.4M+17.3% | $25.5M-33.8% | $22.5M-21.7% | $27.9M-19.7% | $28.5M-22.3% | $38.5M-29.5% | $28.8M-37.0% |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Goodwill | $129.4M0.0% | $129.4M-19.0% | $129.4M-19.0% | $129.4M-24.7% | $129.4M-60.3% | $159.9M-51.0% | $159.9M-51.0% | $171.8M-47.3% |
| Total Liabilities | $399.1M-36.8% | $501.7M-23.9% | $558.2M-18.3% | $603.7M-35.3% | $631.1M-37.5% | $659.1M-36.3% | $683.0M-36.2% | $933.4M-32.1% |
| Current Liabilities | $38.4M-44.9% | $42.6M-32.5% | $44.9M-21.2% | $61.6M-3.4% | $69.7M+1.5% | $63.2M+7.0% | $57.0M-34.9% | $63.7M-18.6% |
| Non-Current Liabilities | $360.7M-35.8% | $459.0M-23.0% | $513.3M-18.0% | $542.2M-37.7% | $561.4M-40.3% | $596.0M-38.9% | $626.0M-36.3% | $869.6M-33.0% |
| Long-Term Debt | $146.0M-49.4% | $235.6M-18.6% | $286.3M-1.4% | $287.4M-44.3% | $288.4M-44.2% | $289.5M-44.1% | $290.5M-44.0% | $516.3M-0.6% |
| Total Equity | $204.6M-23.0% | $211.6M-29.6% | $212.4M-34.7% | $245.4M-28.8% | $265.9M-38.8% | $300.6M-26.8% | $325.3M-21.9% | $344.9M-33.6% |
| Retained Earnings | -$6.0M-108.5% | $6.4M-94.2% | $10.1M-92.8% | $45.8M-72.5% | $71.4M-73.0% | $110.9M-59.5% | $140.9M-50.7% | $166.8M-57.4% |
MRVI Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $4.0M+138.9% | $8.7M+192.3% | -$22.8M-55.5% | -$15.2M-215.3% | -$10.3M-158.9% | -$9.4M-10.9% | -$14.6M-287.9% | $13.1M-7.3% |
| Depreciation & Amortization | $11.8M-10.5% | $11.4M-10.6% | $12.4M+0.6% | $13.2M+10.5% | $13.2M+5.9% | $12.7M+9.2% | $12.4M+14.5% | $11.9M+9.1% |
| Stock-Based Compensation | $10.2M+50.3% | $6.7M-35.2% | N/A | $9.1M-30.6% | $6.8M-50.7% | $10.4M-13.7% | N/A | $13.1M+30.7% |
| Capital Expenditures | $370K-87.1% | $4.4M-1.4% | $2.1M-63.9% | $3.7M-57.4% | $2.9M-69.9% | $4.5M-20.5% | $5.8M-65.2% | $8.6M-45.7% |
| Free Cash Flow | $3.6M+127.6% | $4.2M+130.4% | -$24.9M-21.5% | -$18.8M-513.9% | -$13.1M-266.7% | -$13.9M+1.7% | -$20.5M-127.4% | $4.5M+373.6% |
| Investing Cash Flow | -$370K+88.6% | -$4.4M+80.8% | -$2.1M+57.1% | -$2.9M+67.3% | -$3.2M+47.7% | -$23.1M-445.0% | -$4.9M+61.8% | -$9.0M+42.3% |
| Financing Cash Flow | -$99.0M-6352.4% | -$55.2M-1027.1% | -$1.8M+99.2% | -$8.2M-1119.7% | -$1.5M-772.8% | -$4.9M-775.0% | -$236.2M-50353.0% | $809K+3.3% |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
MRVI Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 40.1%+23.8pp | 51.2%+34.7pp | 25.8%-8.5pp | 13.6%-33.1pp | 16.4%-28.0pp | 16.5%-23.8pp | 34.3%-18.4pp | 46.7%+1.6pp |
| Operating Margin | -29.3% | -3.3% | -117.9% | -98.6% | -139.8% | -104.9% | -66.7%-57.0pp | -239.9% |
| Net Margin | -24.1%+59.4pp | -5.7%+58.3pp | -71.6%-25.9pp | -61.4% | -83.5%-69.4pp | -63.9%-45.1pp | -45.7% | -140.6% |
| Return on Equity | -6.1%+8.8pp | -1.8%+8.2pp | -16.8%-8.9pp | -10.4%+17.7pp | -14.9%-12.6pp | -10.0%-7.0pp | -7.9%+22.1pp | -28.1%-26.9pp |
| Return on Assets | -2.1%+2.4pp | -0.5%+2.6pp | -4.6%-2.1pp | -3.0%+4.6pp | -4.4%-3.7pp | -3.1%-2.3pp | -2.6%+5.9pp | -7.6%-7.3pp |
| Current Ratio | 4.05-1.1x | 5.91-0.1x | 6.60-0.9x | 5.29-5.4x | 5.16-4.8x | 5.96-5.4x | 7.53-0.5x | 10.66+1.7x |
| Debt-to-Equity | 0.71-0.4x | 1.11+0.2x | 1.35+0.5x | 1.17-0.3x | 1.08-0.1x | 0.96-0.3x | 0.89-0.4x | 1.50+0.5x |
| Asset Turnover | 0.090.0x | 0.090.0x | 0.060.0x | 0.050.0x | 0.050.0x | 0.050.0x | 0.060.0x | 0.050.0x |
| FCF Margin | 7.0%+34.8pp | 6.4%+36.1pp | -49.9%-13.7pp | -45.2%-51.8pp | -27.7%-39.1pp | -29.6%-7.6pp | -36.2%-24.1pp | 6.6%+9.1pp |
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Maravai LifeSciences Holdings, Inc. MRVI | FY2025 | $185.7M | -$130.8M | -70.4% | $2.4B | 24/100 |
| MiMedx Group, Inc MDXG | FY2025 | $418.6M | $48.6M | 11.6% | $704.9M | 75/100 |
| CorMedix Inc. CRMD | FY2025 | $311.7M | $163.1M | 52.3% | $581.5M | 50/100 |
| 180 Life Sciences Corp. ATNF | FY2025 | $6.5M | -$450.5M | N/A | $1.1B | 12/100 |
| Oric Pharmaceuticals, Inc. ORIC | FY2025 | N/A | -$129.5M | N/A | $1.2B | — |
Where Maravai LifeSciences Holdings, Inc. Ranks
Frequently Asked Questions
What is Maravai LifeSciences Holdings, Inc.'s annual revenue?
Maravai LifeSciences Holdings, Inc. (MRVI) reported $185.7M in total revenue for fiscal year 2025. This represents a -28.3% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Maravai LifeSciences Holdings, Inc.'s revenue growing?
Maravai LifeSciences Holdings, Inc. (MRVI) revenue declined by 28.3% year-over-year, from $259.2M to $185.7M in fiscal year 2025.
Is Maravai LifeSciences Holdings, Inc. profitable?
No, Maravai LifeSciences Holdings, Inc. (MRVI) reported a net income of -$130.8M in fiscal year 2025, with a net profit margin of -70.4%.
What is Maravai LifeSciences Holdings, Inc.'s EBITDA?
Maravai LifeSciences Holdings, Inc. (MRVI) had EBITDA of -$163.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does Maravai LifeSciences Holdings, Inc. have?
As of fiscal year 2025, Maravai LifeSciences Holdings, Inc. (MRVI) had $216.9M in cash and equivalents against $286.3M in long-term debt.
What is Maravai LifeSciences Holdings, Inc.'s gross margin?
Maravai LifeSciences Holdings, Inc. (MRVI) had a gross margin of 18.3% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is Maravai LifeSciences Holdings, Inc.'s net profit margin?
Maravai LifeSciences Holdings, Inc. (MRVI) had a net profit margin of -70.4% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Maravai LifeSciences Holdings, Inc.'s return on equity (ROE)?
Maravai LifeSciences Holdings, Inc. (MRVI) has a return on equity of -61.6% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Maravai LifeSciences Holdings, Inc.'s free cash flow?
Maravai LifeSciences Holdings, Inc. (MRVI) recorded an outflow of $70.7M in free cash flow during fiscal year 2025. This represents a -218.7% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Maravai LifeSciences Holdings, Inc.'s operating cash flow?
Maravai LifeSciences Holdings, Inc. (MRVI) recorded an outflow of $57.6M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Maravai LifeSciences Holdings, Inc.'s total assets?
Maravai LifeSciences Holdings, Inc. (MRVI) had $770.6M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Maravai LifeSciences Holdings, Inc.'s capital expenditures?
Maravai LifeSciences Holdings, Inc. (MRVI) invested $13.1M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Maravai LifeSciences Holdings, Inc. spend on research and development?
Maravai LifeSciences Holdings, Inc. (MRVI) invested $17.4M in research and development during fiscal year 2025.
What is Maravai LifeSciences Holdings, Inc.'s current ratio?
Maravai LifeSciences Holdings, Inc. (MRVI) had a current ratio of 6.60 as of fiscal year 2025, which is generally considered healthy.
What is Maravai LifeSciences Holdings, Inc.'s debt-to-equity ratio?
Maravai LifeSciences Holdings, Inc. (MRVI) had a debt-to-equity ratio of 1.35 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Maravai LifeSciences Holdings, Inc.'s return on assets (ROA)?
Maravai LifeSciences Holdings, Inc. (MRVI) had a return on assets of -17.0% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Maravai LifeSciences Holdings, Inc.'s P/E ratio?
Maravai LifeSciences Holdings, Inc. (MRVI) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to June 30, 2026). The market capitalization is $2.4B as of Oct 14, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Maravai LifeSciences Holdings, Inc.'s price-to-sales ratio?
Maravai LifeSciences Holdings, Inc. (MRVI) trades at 11.6x sales, its market capitalization divided by revenue of $208.8M revenue, trailing 12 months to June 30, 2026. The market capitalization is $2.4B as of Oct 14, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
How does Maravai LifeSciences Holdings, Inc.'s liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, Maravai LifeSciences Holdings, Inc. (MRVI) held $216.9M in cash, cash equivalents and investments, and reported an operating cash outflow of $57.6M over that year. Dividing the one by the other, the reported balance equals about 45 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
What is Maravai LifeSciences Holdings, Inc.'s Altman Z-Score?
Maravai LifeSciences Holdings, Inc. (MRVI) has an Altman Z-Score of 2.34, placing it in the Grey Zone (moderate risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Maravai LifeSciences Holdings, Inc.'s Piotroski F-Score?
Maravai LifeSciences Holdings, Inc. (MRVI) has a Piotroski F-Score of 1 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Maravai LifeSciences Holdings, Inc.'s earnings high quality?
Maravai LifeSciences Holdings, Inc. (MRVI) reported a net loss of $130.8M while operations used $57.6M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Maravai LifeSciences Holdings, Inc. cover its interest payments?
Maravai LifeSciences Holdings, Inc. (MRVI) reported an operating loss of $215.3M against $27.0M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Maravai LifeSciences Holdings, Inc.?
Maravai LifeSciences Holdings, Inc. (MRVI) scores 24 out of 100 on our Financial Health Score, indicating weak standing within its emerging companies peer group. The score is a 0-100 composite of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.